Milestone Pharmaceuticals Inc (MIST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has a cash flow conversion efficiency ratio of -0.479x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.82 Million) by net assets ($20.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MIST stock market capitalisation for the company's overall valuation and market capitalisation.
Milestone Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Milestone Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore Milestone Pharmaceuticals Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CVRx Inc
NASDAQ:CVRX
|
-0.442x |
|
Heubach Colorants India Limited
NSE:HEUBACHIND
|
N/A |
|
NexMetals Mining Corp. Common Shares
NASDAQ:NEXM
|
-0.150x |
|
Chia Ta World Co Ltd
TW:2033
|
0.042x |
|
Perdana Petroleum Bhd
KLSE:7108
|
0.216x |
|
Wellpool Co Ltd
TWO:8424
|
0.043x |
|
Soke Degirmencilik AS
IS:SOKE
|
0.071x |
|
Vasta Platform Ltd
NASDAQ:VSTA
|
0.020x |
Annual Cash Flow Conversion Efficiency for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Milestone Pharmaceuticals Inc from 2017 to 2024. View Milestone Pharmaceuticals Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.15 Million | $-28.85 Million | -2.194x | +20.73% |
| 2023-12-31 | $16.77 Million | $-46.42 Million | -2.768x | -250.03% |
| 2022-12-31 | $66.35 Million | $-52.47 Million | -0.791x | -168.02% |
| 2021-12-31 | $112.60 Million | $-33.22 Million | -0.295x | +16.76% |
| 2020-12-31 | $143.12 Million | $-50.73 Million | -0.354x | +20.36% |
| 2019-12-31 | $114.92 Million | $-51.15 Million | -0.445x | -216.77% |
| 2018-12-31 | $-55.21 Million | $-21.05 Million | 0.381x | +56.79% |
| 2017-12-31 | $-33.12 Million | $-8.05 Million | 0.243x | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more